Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Li D, Darden C, Sayeed S, Jackson L, Garbinsky D, Osman N. Patient-reported clinical and productivity outcomes from the longitudinal telotristat ethyl treatment registry. Poster presented at the 2021 Virtual Annual Symposium of the North American Neuroendocrine Tumor Society (NANETS); November 3, 2021.
Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021 Sep 7;5(1):82. doi: 10.1186/s41687-021-00355-5
Darden C, Joish VN, Price MA, Garbinsky D, Schwartz S, Warner C, Wason S, Lapuerta P. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the XERMELO patient registry. Poster presented at the NANETS 2020 Multidisciplinary Net Medical Virtual Symposium; October 2, 2020.
Darden C, Ray D, Goldstein G, Goss D, Garbinsky D, Bennett L, Price M, Thota R. Satisfaction survey of administration modes for Long-Acting (LA) Somatostatin Analog (SSA) therapy in patients with Neuroendocrine Tumors (NETS). Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.